CDChirag Dhar

Chirag Dhar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chirag Dhar has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Ajit Varki

    Departments of Medicine and Cellular & Molecular Medicine, University of California, San Diego, CA, 92093, USA; Center for Academic Research and Training in Anthropogeny, University of California, La Jolla, San Diego, CA, USA; Glycobiology Research and Training Center, University of California, La Jolla, San Diego, CA, USA

    6 shared publications
  • Annapurna Vyakarnam

    Centre for Infectious Disease Research, Indian Institute of Science, Bangalore, India

    5 shared publications
  • Aniruddha Sasmal

    University of California San Diego Glycobiology Research and Training Center La Jolla, CA 92093 , USA

    3 shared publications
  • George D. Souza

    Dept. of Pulmonary Medicine & Division of Infectious Diseases, St John’s Research Institute, Bangalore, India

    3 shared publications
  • Pravat Nalini Sahoo

    Laboratory of Immunology of HIV-TB co-infection, Centre for Infectious Disease Research, Indian Institute of Science, Bangalore, India

    3 shared publications
  • Soumya Nayak

    Laboratory of Immunology of HIV-TB co-infection, Centre for Infectious Disease Research, Indian Institute of Science, Bangalore, India

    3 shared publications

Latest Publications

  • Dietary Neu5Ac Intervention Protects Against Atherosclerosis Associated With Human-Like Neu5Gc Loss—Brief Report

    by Kunio Kawanishi, Joanna K. Coker, Kaare V. Grunddal, Chirag Dhar, Jason Hsiao, Karsten Zengler, Nissi Varki, Ajit Varki, Philip L.S.M. Gordts

    Objective: Species-specific pseudogenization of the CMAH gene during human evolution eliminated common mammalian sialic acid N -glycolylneuraminic acid (Neu5Gc) biosynthesis from its precursor N -acetylneuraminic acid (Neu5Ac). With metabolic nonhuman Neu5Gc incorporation into endothelia from red meat, the major dietary source, anti-Neu5Gc antibodies appeared. Human-like Ldlr −/− Cmah −/− mice on a high-fat diet supplemented with a Neu5Gc-enriched mucin, to mimic human red meat consumption, suffered increased atherosclerosis if human-like anti-Neu5Gc antibodies were elicited. Approach and Results: We now ask whether interventional Neu5Ac feeding attenuates metabolically incorporated Neu5Gc-mediated inflammatory acceleration of atherogenesis in this Cmah −/− Ldlr −/− model system. Switching to a Neu5Gc-free high-fat diet or adding a 5-fold excess of Collocalia mucoid-derived Neu5Ac in high-fat diet protects against accelerated atherosclerosis. Switching completely from a Neu5Gc-rich to a Neu5Ac-rich diet further reduces severity. Remarkably, feeding Neu5Ac-enriched high-fat diet alone has a substantial intrinsic protective effect against atherosclerosis in Ldlr −/− mice even in the absence of dietary Neu5Gc but only in the human-like Cmah -null background. Conclusions: Interventional Neu5Ac feeding can mitigate or prevent the red meat/Neu5Gc-mediated increased risk for atherosclerosis, and has an intrinsic protective effect, even in the absence of Neu5Gc feeding. These findings suggest that similar interventions should be tried in humans and that Neu5Ac-enriched diets alone should also be investigated further. Graphic A graphic abstract is available for this article.


  • Open Access

    Are sialic acids involved in COVID-19 pathogenesis?

    by Chirag Dhar, Aniruddha Sasmal, Sandra Diaz, Andrea Verhagen, Hai Yu, Wanqing Li, Xi Chen, Ajit Varki

    We read with much interest the recent mini-review by Sun on the theoretically possible roles of cell surface sialic acids (Sias) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection ( Sun 2021). Given the magnitude of this coronavirus disease 2019 (COVID-19) pandemic ( Lu et al. 2020; Zhu et al. 2020) this question is not just of importance to the glycobiology community, but also to other scientists across many disciplines related to this crisis.


  • Open Access

    Sialoglycan recognition is a common connection linking acidosis, zinc, and HMGB1 in sepsis

    by Shoib S. Siddiqui, Chirag Dhar, Venkatasubramaniam Sundaramurthy, Aniruddha Sasmal, Hai Yu, Esther Bandala-Sanchez, Miaomiao Li, Xiaoxiao Zhang, Xi Chen, Leonard C. Harrison, et al.

    Significance: Sepsis is a condition wherein a microbial infection leads to life-threatening systemic hyperactivation of innate immunity. Blood pH is normally maintained tightly between 7.35 and 7.45, and lactic acidosis with a pH <7.3 indicates a poor prognosis in sepsis, also associated with low zinc levels. Release of HMGB1 from activated and/or necrotic tissues plays a pivotal role in triggering the proinflammatory cascade of late sepsis. Using an in vitro whole-blood assay, we observed that HMGB1 cannot mediate proinflammatory activity at physiological pH and zinc concentrations. This is due to zinc-dependent association of HMGB1 with sialoglycoproteins, thereby preventing its binding with proinflammatory receptors. Thus, a drop in pH and zinc concentration in sepsis can release sequestered HMGB1 and trigger the inflammatory cascade.


  • Open Access

    HIV Skews a Balanced Mtb-Specific Th17 Response in Latent Tuberculosis Subjects to a Pro-inflammatory Profile Independent of Viral Load

    by Srabanti Rakshit, Nitin Hingankar, Shuba Varshini Alampalli, Vasista Adiga, Bharath K. Sundararaj, Pravat Nalini Sahoo, Greg Finak, Anto Jesuraj Uday Kumar J, Chirag Dhar, George D’sOuza, et al.


  • Open Access

    Retrospective study on the clinicogenomic characteristics of EGFR mutant and wildtype NSCLC

    by Chirag Dhar

    Background: Lung cancer is among the leading causes of mortality. Nearly 90% of all lung cancers are histologically classified as non-small cell lung cancer (NSCLC). A subset of these tumors harbor mutations on the epidermal growth factor receptor gene ( EGFR ) and such patients are candidates for targeted therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Aim: To compare and contrast the clinicogenomic characteristics of EGFR mutant and wildtype NSCLC. Methods and results: A retrospective cohort study design was used to analyze publicly available data on cBioPortal.org. Patients with EGFR mutations were more likely to be female, of Asian ethnicity, never-smokers, and diagnosed with lung adenocarcinoma. Metastasis to the pleura, pleural fluid, and liver were common in patients with EGFR mutant NSCLC. On the other hand, lymph node, brain and adrenal gland metastases were more common in patients with other mutations. While the median overall survival was about the same in the two groups, progression free survival was significantly shorter in the EGFR mutant group. The mutational landscape was significantly different in the two groups with EGFR mutant NSCLCs having a lower mutational burden. Differences in copy number alterations between the two groups were also noted. Conclusions: The clinicogenomic profiles of EGFR mutant and EGFR wildtype significantly differ. Further studies on these differences and underlying mechanisms are likely to lead to new “druggable” targets that overcome EGFR TKI resistance.

  • Open Access

    High frequency of exon 20 S768I EGFR mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC

    by George D'SOuza, Chirag Dhar, Vishal Kyalanoor, Lokendra Yadav, Mugdha Sharma, Mohammad Nawaz S, Sweta Srivastava

    Background: Lung cancer is the cause of a fourth of all cancer‐related deaths. About a third of all lung adenocarcinoma tumours harbour mutations on exons 18 to 21 of the epidermal growth factor receptor (EGFR) gene. Detection of these mutations allows for targeted therapies in the form of EGFR Tyrosine kinase inhibitors. Recently, “liquid biopsies” have emerged as an alternative to conventional tissue mutation detection.Aim: In this pilot study, we attempted to optimize EGFR mutation detection from malignant pleural effusions (MPEs) as “liquid biopsies” when tissue biopsies were unavailable. Resulting mutations were then to be mapped on the EGFR gene and explored using cBioPortal, a public cancer genomic database.Methods and results: We first attempted a direct sequencing approach and showed that single nucleotide variants (SNVs) were likely to be missed in MPEs. We then switched to and optimized an EGFR mutant‐specific quantitative polymerase chain reaction‐based assay. This assay was piloted on n = 10 pleural effusion samples (one non‐malignant pleural effusion as a negative control). 5/9 (55.55%) samples harboured EGFR mutations with 2/9 (22.22%) being exon 19 deletions and 3/9 (33.33%) the S768I mutation. The frequency of the S768I SNV in our study was significantly higher than that observed in other studies (~0.2%). Utilizing cBioPortal data, we report that patients with S768I have a shorter median survival time (6 months vs 38 months), progression‐free survival time (8 months vs 44 months) and lower tumor mutation count compared to patients with other EGFR mutations.Conclusions: The shorter survival of patients with the S768I SNV predicts aggressive disease and poor prognosis as a result of this mutation. Studies in larger cohorts and/or animal models are necessary to confirm these findings.


  • Open Access

    Acidosis, Zinc and HMGB1 in Sepsis: A Common Connection Involving Sialoglycan Recognition

    by Shoib S. Siddiqui, Chirag Dhar, Venkatasubramaniam Sundaramurthy, Aniruddha Sasmal, Hai Yu, Esther Bandala-Sanchez, Miaomiao Li, Xiaoxiao Zhang, Xi Chen, Leonard C. Harrison, et al.

    Blood pH is tightly regulated between 7.35-7.45, with values below 7.3 during sepsis being associated with lactic acidosis, low serum zinc, and release of proinflammatory HMGB1 from activated and/or necrotic cells. Using an ex vivo whole blood system to model lactic acidosis, we show that while HMGB1 does not engage leukocyte receptors at physiological pH, lowering pH with lactic acid facilitates binding. At normal pH, micromolar zinc supports plasma sialoglycoprotein binding by HMGB1, which is markedly reduced when pH is adjusted with lactic acid to sepsis levels. Glycan array studies confirmed zinc and pH-dependent HMGB1 binding to sialoglycans typical of plasma glycoproteins. Thus, proinflammatory effects of HMGB1 are suppressed via plasma sialoglycoproteins until drops in pH and zinc release HMGB1 to trigger downstream immune activation. Significance Statement: HMGB1 sequestered by plasma sialoglycoproteins at physiological pH is released when pH and zinc concentrations fall in sepsis.

  • Open Access

    High frequency of Exon 20 S768I EGFR mutation detected in malignant pleural effusions: a poor prognosticator of NSCLC?

    by George D’souza, Chirag Dhar, Vishaal Kyalanoor, Lokendra Yadav, Mugdha Sharmra, Mohammad Nawaz S, Sweta Srivastava

    Lung cancer is the cause of a fourth of all cancer-related deaths. About a third of all lung adenocarcinoma tumours harbour mutations on exons 18, 19, 20 and 21 of the epidermal growth factor receptor (EGFR) gene. Detection of these mutations allows for targeted therapies in the form of EGFR Tyrosine kinase inhibitors. In our study, we utilized malignant pleural effusions (MPEs) as “liquid biopsies” to detect EGFR mutations when tissue biopsies were unavailable. We showed that a direct sequencing approach was likely to miss SNVs in MPEs. We then optimized an EGFR mutant-specific quantitative polymerase chain reaction-based assay and piloted it on n=10 pleural effusion samples (1 non-malignant pleural effusion as a negative control). 5/9 (55.55%) samples harboured EGFR mutations with 2/9 (22.22%) being exon 19 deletions and 3/9 (33.33%) had the S768I exon 20 mutation. The frequency of the S768I SNV in our study was significantly higher than that observed in other studies (∼0.3%). Utilizing publicly available cBioPortal data, we report that patients with the S768I SNV had a shorter median survival time, progression-free survival time and lower tumor mutation count compared to patients with other EGFR mutations. These data suggest that this point mutation predicts poor prognosis as a result of aggressive disease, though studies in larger cohorts are necessary to confirm these findings. The high frequency of S768I mutations seen in our study also suggests that cancer cells harbouring these mutations may be superior in their ability to migrate, home or reside in pleural fluid.

  • Open Access

    Clinical practice alert on the use of immune checkpoint inhibitors in patients latently infected with tuberculosis

    by Chirag Dhar

    Multiple case reports have been published on the risk of tuberculosis activation in patients on immune checkpoint inhibitors (ICPIs). To this matter, I caution clinicians to test for latent tuberculosis before starting their patients on ICPIs.

  • Human species-specific loss of CMP- N -acetylneuraminic acid hydroxylase enhances atherosclerosis via intrinsic and extrinsic mechanisms

    by Kunio Kawanishi, Chirag Dhar, Raymond Do, Nissi Varki, Philip L. S. M. Gordts, Ajit Varki

    Cardiovascular disease (CVD) events due to atherosclerosis cause one-third of worldwide deaths and risk factors include physical inactivity, age, dyslipidemia, hypertension, diabetes, obesity, smoking, and red meat consumption. However, ∼15% of first-time events occur without such factors. In contrast, coronary events are extremely rare even in closely related chimpanzees in captivity, despite human-like CVD–risk-prone blood lipid profiles, hypertension, and mild atherosclerosis. Similarly, red meat-associated enhancement of CVD event risk does not seem to occur in other carnivorous mammals. Thus, heightened CVD risk may be intrinsic to humans, and genetic changes during our evolution need consideration. Humans exhibit a species-specific deficiency of the sialic acid N-glycolylneuraminic acid (Neu5Gc), due to pseudogenization of cytidine monophosphate-N-acetylneuraminic acid (Neu5Ac) hydroxylase (CMAH), which occurred in hominin ancestors ∼2 to 3 Mya. Ldlr−/− mice with human-like Cmah deficiency fed a sialic acids (Sias)-free high-fat diet (HFD) showed ∼1.9-fold increased atherogenesis over Cmah wild-type Ldlr−/− mice, associated with elevated macrophage cytokine expression and enhanced hyperglycemia. Human consumption of Neu5Gc (from red meat) acts as a “xeno-autoantigen” via metabolic incorporation into endogenous glycoconjugates, as interactions with circulating anti-Neu5Gc “xeno-autoantibodies” potentiate chronic inflammation (“xenosialitis”). Cmah−/−Ldlr−/− mice immunized with Neu5Gc-bearing antigens to generate human-like anti-Neu5Gc antibodies suffered a ∼2.4-fold increased atherosclerosis on a Neu5Gc-rich HFD, compared with Neu5Ac-rich or Sias-free HFD. Lesions in Neu5Gc-immunized and Neu5Gc-rich HFD-fed Cmah−/−Ldlr−/− mice were more advanced but unexplained by lipoprotein or glucose changes. Human evolutionary loss of CMAH likely contributes to atherosclerosis predisposition via multiple intrinsic and extrinsic mechanisms, and future studies could consider this more human-like model. Significance Cardiovascular disease (CVD) events like heart attacks and strokes due to atherosclerotic narrowing of arteries are the commonest cause of worldwide deaths, but many first-time events occur in individuals without known risk factors. In contrast, such events are extremely rare in other animals despite some of the same risk factors. While environmental and behavioral factors likely contribute to the difference, we show here that a human-specific genetic mutation affecting cell-surface molecules called sialic acids may be one other factor. We also show that the same mutation can help explain the apparently human-specific increased risk of CVD events associated with red meat consumption. The humanized mouse systems we present could be explored as models for future studies of atherosclerosis.